Johnson & Johnson received FDA approval for INLEXZO, a new treatment for certain types of bladder cancer. This drug is for patients who have not responded to BCG therapy and cannot undergo bladder removal surgery. INLEXZO delivers therapy directly to the bladder and has shown an 82% complete response rate. This innovative approach offers hope for those with BCG-unresponsive, non-muscle invasive bladder cancer. Visit rttnews.com for more health news.

Read more at Nasdaq: FDA Approves Johnson & Johnson’s INLEXZO For BCG-Unresponsive Bladder Cancer